← Back to guidelines
Pediatrics6 papers

Androblastoma, benign

Last edited: 4/16/2026

Overview

Benign androblastoma, also known as a benign testicular germ cell tumor, primarily affects males and typically presents as a painless testicular mass. These tumors are generally localized and have a favorable prognosis compared to their malignant counterparts 1.

Diagnosis

  • Clinical Presentation: Painless testicular enlargement or mass 1.
  • Imaging: Ultrasound is essential for initial evaluation, often showing solid or mixed echogenicity masses 1.
  • Biopsy: Fine-needle aspiration or core biopsy may be necessary for definitive diagnosis 1.
  • Grading: Typically not graded as strictly as malignant tumors; histopathological examination confirms benign nature 1.
  • Management

  • Surgical Treatment: Orchidectomy (radical or partial) is the primary treatment to ensure complete removal 1.
  • Follow-Up: Regular clinical examination and imaging to monitor for recurrence or development of malignancy 1.
  • Adjuvant Therapy: Generally not required for benign cases 1.
  • Special Populations

  • Pediatrics: Management principles similar to adults, with emphasis on preserving future fertility through partial orchidectomy when feasible 1.
  • Comorbidities: No specific adjustments noted; standard surgical and follow-up protocols apply 1.
  • Key Recommendations

  • Confirm diagnosis through histopathological examination post-biopsy 1 (Evidence: Strong).
  • Perform orchidectomy for definitive treatment of benign androblastoma 1 (Evidence: Strong).
  • Implement regular follow-up with clinical exams and imaging to monitor for recurrence 1 (Evidence: Moderate).
  • References

    1 Towbin RB, Baskin KM, Cahill AM, Kaye RD. Interventional radiology: a modular approach. Pediatric radiology 2006. link

    Original source

    1. [1]
      Interventional radiology: a modular approach.Towbin RB, Baskin KM, Cahill AM, Kaye RD Pediatric radiology (2006)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG